Stock ALPMY ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Market Closed - OTC Markets
Other stock markets
 15:59:59 2024-05-24 EDT 		5-day change 1st Jan Change
9.99 USD +1.32% Intraday chart for Astellas Pharma Inc. +5.38% -16.05%
05-21 Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
05-16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ

Evolution of the average Target Price on Astellas Pharma Inc.

Price target over the last 5 years

History of analyst recommendation changes

e7f78dafb2a.CsBT_-malLLfeMwRMxkM2wD8qiyZrPiFAHx53BUxBeI.XvAlkdvI0_e4ILkiek94qFqx2kndlMHUZh4P7VMFVrV6gxuQiODf4YZVlQ~fff26370dffcbe4afcb0cf97eb96049b

Analyst Recommendations on Astellas Pharma Inc.

Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Adjusts Astellas Pharma’s Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen MT
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy MT
Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Adjusts Price Target to 2,200 Yen From 2,100 Yen MT
Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,566 JPY
Average target price
1,966 JPY
Spread / Average Target
+25.56%
High Price Target
3,170 JPY
Spread / Highest target
+102.49%
Low Price Target
1,200 JPY
Spread / Lowest Target
-23.35%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Astellas Pharma Inc.

Jefferies & Co.

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. ALPMY Stock
  5. Consensus Astellas Pharma Inc.